Angiogenic cytokines in patients with idiopathic interstitial pneumonia
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    VEGF in idiopathic interstitial pneumonia

    Dear Editor

    Simler et al. raise an interesting possibility of the prognostic value of plasma VEGF in interstitial lung disease. Meyer et al. in a previous study [1] did not find any difference in serum VEGF165 levels in patients with diffuse parenchymal lung disease. It would have been interesting to know the BALF VEGF levels of these patients as Meyer et al.and Koyama et al. [2] have shown reduced BAL fluid VEGF...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    Angiogenic growth factors in idiopathic interstitial pneumonia
    • David r Thickett, senior lecturer in medical sciences
    • Other Contributors:
      • Alex G Richter, Gavin D Perkins, Elizabeth O Maughan, Nazim Nathani

    Dear Editor

    We read with interest the recent article from Simler et al in Thorax investigating angiogenic cytokines in patients with idiopathic interstitial pneumonia [1]. We were surprised by their reported high levels of plasma VEGF in the normal control group. Previously, several other groups, including the manufacturers of the ELISA (R&D systems) quote normal plasma VEGF levels in the range of 36-76 pg/...

    Show More
    Conflict of Interest:
    None declared.